Nanochon Completes First Case in Chondrograft™ First-in-Human Clinical Study
Nanochon, a medical device company developing the patented implant Chondrograft™ for knee cartilage repair, has successfully treated its first patient as part of its First-in-Human (FIH) clinical study. The procedure was performed by Drs. Juan Osorio and Emilio Tufiño at The Panama Clinic in Panamá on September 2, 2026. This milestone marks a key step toward generating the clinical data needed for future pivotal trials. Chondrograft™ is designed as a minimally invasive solution to treat focal cartilage defects and aims to provide durable mechanical support while enabling tissue regeneration. The FIH study will enroll patients aged 22–60 who have not responded well to conservative treatments. Nanochon plans to move forward with a Level 1 multi-center, randomized clinical trial following the completion of this initial phase. The company has received Breakthrough Device Designation from the FDA and aims to redefine treatment options for cartilage injuries by potentially delaying or eliminating the need for knee replacement in younger patients.
Topics: 3d printing in medicine biomedical innovation cartilage repair